Chemistry & Biology, Modeling & Immunology for Therapy

Team Composition

 

 

Jean-Philippe Herbeuval, DR

Staff

Mathieu Rodero, CR
Armelle Melet, MCU
Sabrina Guermah, ADT

Researcher
Dominique Cathelin

Post Docs
Birgit Caspar

PhD Students
Nassima Bekaddour
Thomas Moreau
Margaux Cescato
Severine Grinberg

Industrial Partnership

Ermium Therapeutics

Created in 2012, the research axes of the team focus on the regulation of cytokine production during viral infection and inflammation in autoimmune diseases.

Scientific projects and goals:

  • Drug discovery:

The laboratory generates and optimizes original screening assays dedicated to the identification of immune modulatory molecules. These assays are used to screen in house or external libraries.

Once identify, the lab have an establish work flow to validate lead compounds, going from in house chemical optimization, evaluation on in vitro and vivo model of inflammation and infection, to evaluation on material from patients with autoimmune disease such as lupus.

CXCR4 dependent immune regulation in inflammatory and infectious models.

We have recently shown that some small endogenous amines regulate interferon and cytokine production in innate immune cells by engaging the chemokine receptor CXCR4. Our future projects aim to design, synthetize and characterize small compounds able to modulate inflammation through CXCR4. Furthermore, it is essential to understand the molecular mechanism by which natural amines regulate innate immunity. Our discoveries have a great potential in clinics for treating auto-immune diseases like lupus or chronic infectious diseases as HIV.

  • Pathophysiology of inflammatory and autoimmune diseases.

Our work on adult and paediatric rare immune diseases aim to better understand the pathophysiology and guide therapeutic approaches. Our studies on the contribution of infection and interferon to the onset of juvenile dermatomyositis led to a clinical trial evaluating blocker of interferon signalling (JAK inhibitors) as first line treatment in this disease. In parallel, we are interested by the genotype /phenotype correlation in rare dysimmune genetic diseases, notably in regards to the specificity of the responses to treatments.

Chemistry & Biology, Modeling & Immunology for Therapy

Team composition

 

Researcher
Dominique Cathelin

Post Docs
Birgit Caspar

PhD Students
Nassima Bekaddour
Thomas Moreau
Margaux Cescato
Severine Grinberg

Industrial Partnership

Ermium Therapeutics

 

Created in 2012, the research axes of the team focus on the regulation of cytokine production during viral infection and inflammation in autoimmune diseases.

Scientific projects and goals:

  • Drug discovery:

The laboratory generates and optimizes original screening assays dedicated to the identification of immune modulatory molecules. These assays are used to screen in house or external libraries.

Once identify, the lab have an establish work flow to validate lead compounds, going from in house chemical optimization, evaluation on in vitro and vivo model of inflammation and infection, to evaluation on material from patients with autoimmune disease such as lupus.

CXCR4 dependent immune regulation in inflammatory and infectious models.

We have recently shown that some small endogenous amines regulate interferon and cytokine production in innate immune cells by engaging the chemokine receptor CXCR4. Our future projects aim to design, synthetize and characterize small compounds able to modulate inflammation through CXCR4. Furthermore, it is essential to understand the molecular mechanism by which natural amines regulate innate immunity. Our discoveries have a great potential in clinics for treating auto-immune diseases like lupus or chronic infectious diseases as HIV.

    • Pathophysiology of inflammatory and autoimmune diseases.

    Our work on adult and paediatric rare immune diseases aim to better understand the pathophysiology and guide therapeutic approaches. Our studies on the contribution of infection and interferon to the onset of juvenile dermatomyositis led to a clinical trial evaluating blocker of interferon signalling (JAK inhibitors) as first line treatment in this disease. In parallel, we are interested by the genotype /phenotype correlation in rare dysimmune genetic diseases, notably in regards to the specificity of the responses to treatments.

    Main Publications

    Fayand A, et al: Successful treatment of JAK1 associated inflammatory disease. J Allergy Clin Immunol. 2023

    Rodero M, et al: Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection. J Clin Immunol 2022

    Smith N, et al: Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement-A new target for lupus treatment. Sci Adv 2019

    Müller J et al. Semen inhibits Zika virus infection of cells and tissues from the anogenital region. Nat Commun. 2018

    Smith N et al. Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement. Nat Commun. 2017